TearScience has launched a new consumer education portal, DryEyeandMGD.com. The website is an additional resource for eye care practices to educate about meibomian gland dysfunction (MGD)—the leading cause of dry eye—and how it can be identified and effectively treated.
There are nearly 30 million people in the US and over 300 million worldwide who have been diagnosed with dry eye. It is estimated that about 86% of dry eye cases are caused by MGD, according to a company news release. DryEyeandMGD.com is a place where patients can learn about what causes MGD and how to prevent the disease from worsening.
“Millions suffer from meibomian gland dysfunction, or MGD, and yet most don’t know it’s causing their dry eye. Even more have the disease and don’t know it because they are not yet symptomatic. The goal of the new site is to inform and elevate knowledge about MGD so that patients can take action to prevent permanent gland loss,” said Dr. Joe Boorady, President and CEO of TearScience, in the news release.
MGD occurs when the protective oil that normally flows from the meibomian glands located in the eyelids (called meibum) slows or stops. Meibum acts as the front line of protection for the tears and lubricates the surface of the eyes during blinking. Over time, if blockage persists in the meibomian glands, structural damage can occur. A potential result of the meibomian glands not producing enough meibum is that the tear film rapidly evaporates, leaving the eye’s surface exposed. This exposure can cause discomfort that increases over time, causing negative effects on quality of vision, uncomfortable contact lens wear and other irritating dry eye symptoms.
The new website features a user interface in scrolling format to simplify navigation on desktop and mobile devices. In addition to the educational resources, visitors to the site can also locate a provider in their area who offers treatment for MGD with the TearScience LipiFlow Thermal Pulsation System.